News

June 2, 2017

Novo Seeds portfolio company Dermtreat launches phase 1b study

Danish-based Dermtreat today announced the launch of its phase 1b study of the Rivelin® patch – a breakthrough therapy in treating mucosal diseases.

Dermtreat has developed the Rivelin® patch – a breakthrough therapy for the treatment of mucosal diseases. Rivelin® is designed to deliver a pharmaceutical drug uni-directional to a mucosal surface – using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface.